Chronic myelogenous leukemia, version 1.2014: Featured updates to the NCCN guidelines

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 11, Issue 11, 2013, Pages 1327-1340

  O'Brien, Susan ^a   Radich, Jerald P ^b   Abboud, Camille N ^c   Akhtari, Mojtaba ^d   Altman, Jessica K ^e   Berman, Ellin ^f   DeAngelo, Daniel J ^g   Deininger, Michael ^h   Devine, Steven ⁱ   Fathi, Amir T ^j   Gotlib, Jason ^k   Jagasia, Madan ^l   Kropf, Patricia ^m   Moore, Joseph O ⁿ   Pallera, Arnel ^o   Pinilla Ibarz, Javier ^p   Reddy, Vishnu V B ^q   Shah, Neil P ^r   Douglas Smith, B ^s   Snyder, David S ^t   Wetzler, Meir ^u   Gregory, Kristina ^v   Sundar, Hema ^v   more..

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b SEATTLE CANCER CARE ALLIANCE   (United States)

^c BARNES JEWISH HOSPITAL   (United States)

^d NEBRASKA MEDICAL CENTER   (United States)

^e NORTHWESTERN UNIVERSITY   (United States)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^g Dana Farber Brigham and Women's Cancer Center   (United States)

^h UNIVERSITY OF UTAH   (United States)

ⁱ OHIO STATE UNIVERSITY   (United States)

^j MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^k STANFORD CANCER INSTITUTE   (United States)

^l VANDERBILT INGRAM CANCER CENTER   (United States)

^m FOX CHASE CANCER CENTER   (United States)

ⁿ DUKE CANCER INSTITUTE   (United States)

^o UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^p H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^q UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^r UNIVERSITY OF CALIFORNIA   (United States)

^s JOHNS HOPKINS UNIVERSITY   (United States)

^t CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^u ROSWELL PARK CANCER INSTITUTE   (United States)

^v National Comprehensive Cancer Network   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; DASATINIB; IMATINIB; MESSENGER RNA; NILOTINIB; PONATINIB; PROTEIN TYROSINE KINASE INHIBITOR;

BONE MARROW; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CHRONIC MYELOID LEUKEMIA; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); CONTINUING EDUCATION; CYTOGENETICS; DIAGNOSTIC TEST ACCURACY STUDY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FOLLOW UP; HUMAN; ONCOLOGY; OVERALL SURVIVAL; PATIENT COMPLIANCE; PATIENT MONITORING; POINT MUTATION; PRACTICE GUIDELINE; PROGRESSION FREE SURVIVAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; STANDARDIZATION; TREATMENT PLANNING; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PROGNOSIS; PROTEIN KINASE INHIBITORS;

EID: 84891954191     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2013.0157     Document Type: Review

References (48)

1. Faderl S, Talpaz M, Estrov Z, Kantarjian HM. Chronic myelogenous leukemia: biology and therapy. Ann Intern Med 1999;131:207-219.
2. Verma D, Kantarjian HM, Jones D, et al. Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance. Blood 2009;114:2232-2235.
3. Deininger M, O'Brien SG, Guilhot F, et al. International randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib [abstract]. Blood 2009;114:Abstract 1126.
4. Hochhaus A, Shah NP, Cortes JE, et al. Dasatinib versus imatinib (IM) in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): DASISION 3-year follow-up [abstract]. J Clin Oncol 2012;30(Suppl):Abstract 6504.
5. Larson RA, Hochhaus A, Hughes TP, et al. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia 2012;26:2197-2203.
6. Shah NP, Kim D-W, Kantarjian H, et al. Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib. Haematologica 2010;95:232-240.
7. Shah NP, Kantarjian H, Kim DW, et al. Six-year (yr) follow-up of patients (pts) with imatinib-resistant or -intolerant chronic-phase chronic myeloid leukemia (CML-CP) receiving dasatinib [abstract]. J Clin Oncol 2012;30(Suppl):Abstract 6506.
8. Giles FJ, le Coutre PD, Pinilla-Ibarz J, et al. Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study. Leukemia 2013;27:107-112.
9. Khoury HJ, Cortes JE, Kantarjian HM, et al. Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. Blood 2012;119:3403-3412.
10. Cortes JE, Kim DW, Pinilla-Ibarz J, et al. A pivotal phase 2 trial of ponatinib in patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) resistant or intolerant to dasatinib or nilotinib, or with the T315I BCR-ABL mutation: 12-month follow-up of the PACE trial [abstract]. Blood 2012;120:Abstract 163.
11. Kantarjian HM, Talpaz M, Cortes J, et al. Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; Gleevec) in chronic-phase chronic myelogenous leukemia. Clin Cancer Res 2003;9:160-166.
12. Hughes T, Deininger M, Hochhaus A, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006;108:28-37.
13. Hughes T, Kaeda J, Branford S, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003;349:1423-1432.
14. Beillard E, Pallisgaard N, van der Velden VH, et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR): a Europe Against Cancer program. Leukemia 2003;17:2474-2486.
15. Cortes J, Talpaz M, O'Brien S, et al. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Clin Cancer Res 2005;11:3425-3432.
16. Branford S, Cross NCP, Hochhaus A, et al. Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia. Leukemia 2006;20:1925-1930.
17. Cross NC. Standardisation of molecular monitoring for chronic myeloid leukaemia. Best Pract Res Clin Haematol 2009;22:355-365.
18. Branford S, Fletcher L, Cross NC, et al. Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. Blood 2008;112:3330-3338.
19. Radich JP, Kopecky KJ, Appelbaum FR, et al. A randomized trial of dasatinib 100 mg vs imatinib 400 mg in newly diagnosed chronic phase chromic myeloid leukemia. Blood 2012;120:3898-3905.
20. Muller MC, Cortes JE, Kim D-W, et al. Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations. Blood 2009;114:4944-4953.
21. Hughes T, Saglio G, Branford S, et al. Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase. J Clin Oncol 2009;27:4204-4210.
22. Hochhaus A, Kim D-W, Pinilla-Ibarz J, et al. Molecular responses with ponatinib in patients with Philadelphia chromosome positive (Ph+) leukemia: results from the PACE trial [abstract]. Blood 2012;120:Abstract 3763.
23. Deininger MWN, Cortes JE, Kim DW, et al. Impact of baseline mutations on response to ponatinib and end of treatment mutation analysis in patients with chronic myeloid leukemia [abstract]. J Clin Oncol 2013;31(Suppl):Abstract 7001.
24. Jabbour E, Branford S, Saglio G, et al. Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia. Cancer 2011;117:1800-1811.
25. Soverini S, Hochhaus A, Nicolini FE, et al. BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood 2011;118:1208-1215.
26. Branford S, Rudzki Z, Parkinson I, et al. Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations. Blood 2004;104:2926-2932.
27. Wang L, Knight K, Lucas C, Clark R. The role of serial BCR-ABL transcript monitoring in predicting the emergence of BCR-ABL kinase mutations in imatinib-treated patients with chronic myeloid leukemia. Haematologica 2006;91:235-239.
28. Kantarjian HM, Shan J, Jones D, et al. Significance of increasing levels of minimal residual disease in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic response. J Clin Oncol 2009;27:3659-3663.
29. Marin D, Khorashad JS, Foroni L, et al. Does a rise in the BCR-ABL1 transcript level identify chronic phase CML patients responding to imatinib who have a high risk of cytogenetic relapse? Br J Haematol 2009;145:373-375.
30. Press RD, Willis SG, Laudadio J, et al. Determining the rise in BCR-ABL RNA that optimally predicts a kinase domain mutation in patients with chronic myeloid leukemia on imatinib. Blood 2009;114:2598-2605.
31. Branford S, Rudzki Z, Harper A, et al. Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Leukemia 2003;17:2401-2409.
32. Quintas-Cardama A, Kantarjian H, Jones D, et al. Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy. Blood 2009;113:6315-6321.
33. Marin D, Ibrahim AR, Lucas C, et al. Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol 2012;30:232-238.
34. Hanfstein B, Muller MC, Hehlmann R, et al. Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia 2012;26:2096-2102.
35. Neelakantan P, Gerrard G, Lucas C, et al. Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies. Blood 2013;121:2739-2742.
36. Saglio G, Kantarjian HM, Shah N, et al. Early response (molecular and cytogenetic) and long-term outcomes in newly diagnosed chronic myeloid leukemia in chronic phase (CMLCP): exploratory analysis of DASISION 3-year data [abstract]. Blood 2012;120:Abstract 1675.
37. Saglio G, Hughes TP, Larson RA, et al. Impact of early molecular response to nilotinib (NIL) or imatinib (IM) on the long-term outcomes of newly diagnosed patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP): landmark analysis of 4-year (y) data from ENESTnd [abstract]. J Clin Oncol 2013;31(Suppl):Abstract 7054.
38. Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010;362:2260-2270.
39. Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010;362:2251-2259.
40. Jain P, Kantarjian H, Nazha A, et al. Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities. Blood 2013;121:4867-4874.
41. Milojkovic D, Apperley JF, Gerrard G, et al. Responses to second-line tyrosine kinase inhibitors are durable: an intention-to-treat analysis in chronic myeloid leukemia patients. Blood 2012;119:1838-1843.
42. Branford S, Kim DW, Soverini S, et al. Initial molecular response at 3 months may predict both response and event-free survival at 24 months in imatinib-resistant or -intolerant patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase treated with nilotinib. J Clin Oncol 2012;30:4323-4329.
43. Kim DD, Lee H, Kamel-Reid S, Lipton JH. BCR-ABL1 transcript at 3 months predicts long-term outcomes following second generation tyrosine kinase inhibitor therapy in the patients with chronic myeloid leukaemia in chronic phase who failed Imatinib. Br J Haematol 2013;160:630-639.
44. Yeung DT, Osborn MP, White DL, et al. Early switch to nilotinib does not overcome the adverse outcome for cml patients failing to achieve early molecular response on imatinib, despite excellent overall outcomes in the TIDEL II trial [abstract]. Blood 2012;120:Abstract 3771.
45. Montani D, Bergot E, Gunther S, et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation 2012;125:2128-2137.
46. Giles FJ, Mauro MJ, Hong F, et al. Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or nontyrosine kinase therapy: a retrospective cohort analysis. Leukemia 2013;27:1310-1315.
47. Khoury HJ, Cortes JE, Kim DW, et al. Analysis of the cardiovascular risk profile of Ph+ leukemia patients treated with ponatinib [abstract]. J Clin Oncol 2013;31(Suppl):Abstract 7048.
48. Nazha A, Kantarjian HM, Jain P, et al. Disease patterns for patients (pts) with chronic myeloid leukemia (CML) that have BCR-ABL transcript levels > 10% at 3 month of therapy with tyrosine kinase inhibitors (TKIs) [abstract]. Blood 2012;120:Abstract 3757.